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Further reduction of mother-to-child transmission (MTCT) of HIV requires improved 
understanding of the reasons for MTCT. We reviewed maternal and infant case notes for HIV-
positive infants diagnosed by polymerase chain reaction at Bethesda Hospital. Nineteen cases 
were analysed. Median gestation at first antenatal consultation (ANC) was 22.5 (interquartile 
range [IQR] 19.25–24). Eleven (57.9%) mothers were HIV positive at first ANC, whilst eight 
tested negative and later positive (2 antepartum, 6 postpartum). Median maternal CD4 was 
408 cells/μL (IQR 318–531). Six (31.6%) received no antenatal antiretroviral therapy (ART) 
because they were diagnosed as HIV positive postpartum; 9 (47.3%) received antenatal ART 
and 3 (15.8%) were never initiated on ART. At 6 weeks postpartum, 5 infants (26.3%) were 
not on prophylactic nevirapine (NVP) because their mothers had not yet been diagnosed. 
Maternal seroconversion in pregnancy and breastfeeding, and possibly false-negative HIV 
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In 2010, the South African Department of Health (DoH) prevention of mother-to-child transmission 
(PMTCT) guidelines recommended World Health Organization Option A (prophylactic 
zidovudine [AZT] for women with a CD4+ count > 350 cells/μL and combination antiretroviral 
therapy [cART] for all pregnant women with CD4 < 350 cells/μL, with subsequent infant 
nevirapine [NVP] for a minimum of 6 weeks).1 Option B (cART for all pregnant and breastfeeding 
women irrespective of CD4 count and postnatal infant NVP prophylaxis) was introduced in April 
2013.2 Using these guidelines, mother-to-child transmission (MTCT) in KwaZulu-Natal, South 
Africa, dropped from 20.8% at 6 weeks postpartum in 2005 to 2.1% in 2011,3,4 with a national 
target of less than 2% by 2016.5 Further reduction will require a better understanding of the 
reasons for PMTCT failure in local facilities. Seroconversion in pregnancy or breastfeeding, HIV 
diagnosis in pregnancy compared with diagnosis prior to conception, and health system-related 
factors have all been found to play a role in PMTCT failure.6,7,8
Bethesda is a rural district hospital serving approximately 115 000 people in Umkhanyakude 
District, KwaZulu-Natal Province, with an HIV prevalence of 41.1% amongst pregnant women 
in 2011.9 HIV polymerase chain reaction (PCR) positivity at 6 weeks postpartum in 2013 was 
2.3% for Bethesda Hospital (personal comm., Facility Information Officer, n.d.) and its eight 
peripheral primary healthcare clinics. Our aim was to identify reasons for these PMTCT 
failures.
Methods
We retrospectively reviewed maternal and infant case notes for HIV-positive infants identified by 
HIV PCR between February and September 2013 at Bethesda Hospital and its clinics.
Ethics approval
Ethics approval for the study was granted by the University of KwaZulu-Natal Biomedical 
Research Ethics Committee and the KwaZulu-Natal Health Research Committee.
Results
A total of 25 cases of MTCT were identified in the study period. Data were available for analysis 
in 19 cases (Table 1). Notes were often incomplete, meaning data were not available for all 19 
cases for some variables. Median maternal age was 22 years (interquartile range [IQR] 20.5–
28). Median gestation at first antenatal consultation (ANC) was 22.5 weeks (IQR 19.25–24) and 
9 (47.3%) women were known to have had their first ANC after 20 weeks’ gestation. Five (26.3%) 
women were known to be HIV positive preconception. A further 6 (31.6%) tested HIV positive 
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at first ANC. Eight (42.1%) tested HIV negative at first ANC, 
but two of these subsequently tested positive antenatally (1 
and 3 weeks before delivery respectively). The remaining 
6 (31.6%) women tested HIV positive postpartum. Median 
maternal CD4 at baseline was 408 cells/μL (IQR 318–531). 
Of the 13 who were known to be HIV positive before 
delivery, 1/13 (7.7%) had unknown antenatal antiretroviral 
therapy (ART) status, 3/13 (23.1%) were never initiated on 
ART before delivery, 3/13 (23.1%) were already on cART 
pre-conception, and 6/13 (46.2%) were initiated on ART 
antenatally (cART = 4, AZT monotherapy = 2) at a median 
of 28 weeks’ gestation (IQR 26–30) and 0 days (IQR 0–16) 
after being diagnosed as requiring PMTCT. One of these 
patients had a documented history of poor adherence/
defaulting. The six patients diagnosed postpartum did not 
have information on maternal ART initiation available. Of 
the three patients on cART pre-conception, 2 had viral loads 
taken antenatally and both were greater than 400 copies/
mL. Five women had caesarean sections.
Regarding infants, 5 (26.3%) were not on NVP at their 6-week 
postnatal follow-up visit because their mothers had not yet 
tested HIV positive. Of the remaining 14 subjects, only 8/14 
(57.1%) infants were documented to be on NVP prophylaxis, 
with 6/14 (42.9%) having no record of NVP administered. 
Two (10.5%) infants were documented as receiving mixed 
feeding at 6 weeks. One (5.3%) infant died before cART 
initiation, and 13 (68.4%) were known to have been initiated 
on cART at a median 5 (IQR 3–11) weeks after diagnosis.
Discussion
Maternal and infant ART have consistently been shown to 
be highly efficacious for PMTCT; consequently, omitting 
or delaying ART exposes infants to unnecessary HIV 
transmission risks.10 In the present study, we repeat 
findings elsewhere6,8 that initially testing HIV negative and 
subsequently positive in pregnancy or breastfeeding (leading 
to delays in ART initiation) is a major cause of PMTCT 
failure, occurring in 8 (42.1%) of the PMTCT failure cases in 
our study. We could not determine whether this was because 
of an initial false-negative test, or maternal seroconversion in 
the majority of cases. Current PMTCT guidelines advocate 
TABLE 1: Maternal and infant characteristics.
Characteristics Sub-characteristics n % Median IQR
Variable Maternal age (years) 19 - 22 20.5–28
Gestation at first ANC (weeks) 14 (5 unknown) - 22.5 19.3–24
Maternal CD4 (cells/μL) 14 (5 unknown) - 408 318–531
Weeks from infant diagnosis to ART initiation 13 (6 unknown) - 5 3–11
Maternal HIV status at first ANC Positive 11 57.9 - -
Negative 8 42.1 - -
Period of maternal HIV diagnosis Pre-conception 5 26.3 - -
Antenatal 8 42.1 - -
Postpartum 6 31.6 - -
Antenatal ART regimen None because diagnosed postnatally 6 31.6 - -
cART 7 36.8 - -
Prophylactic AZT 2 10.5 - -
No ART 3 15.8 - -
Unknown 1 5.3 - -
Delivery Normal vaginal delivery 12 63.2 - -
Caesarean section 5 26.3 - -
Unknown 2 10.5 - -
Gestation at delivery (weeks) 14 (5 unknown) - 38 36–38
Infant NVP prophylaxis at 6 weeks 
postpartum?
Yes 8 42.1 - -
No† 6† 31.6 - -
Unknown 5 26.3 - -
Infant feeding method at 6 weeks 
postpartum?
Exclusive breastfeeding 8 42.1 - -
Exclusive formula feeding 3 15.8 - -
Mixed feeding 2 10.5 - -
Unknown 6 31.6 - -
N = 19.
n = number of cases per category; ANC, antenatal consultation; ART, antenatal antiretroviral therapy; cART, combination antiretroviral therapy; AZT, prophylactic zidovudine; NVP, nevirapine; IQR, 
interquartile range.
†, Five infants were not on NVP at their 6-week postnatal follow-up visit because their mothers had not yet tested HIV positive.
Note: The depth of the columns represents how early a maternity case was identified as 
HIV positive.
ANC, antenatal consultation; AZT, prophylactic zidovudine.
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a confirmatory second HIV rapid test if the initial test is 
positive. However, there is no confirmatory test if the first 
test is negative.2 A study of 967 adults presenting for HIV 
testing in a clinic in Durban found that 2.1% of patients with 
a negative rapid HIV test had either acute HIV infection 
(which was missed by the rapid test because of falling within 
the ‘window period’) or chronic HIV infection (i.e. a false-
negative rapid test).11 In the context of further reducing MTCT 
to below 2%, potentially misdiagnosing 2% of mothers living 
with HIV is significant. Strategies to increase detection of 
all positive cases could include a second confirmatory rapid 
test as routine in all pregnant women (with an HIV ELISA 
confirmatory test for all discordant results). Furthermore, 
regular 3-monthly maternal HIV testing throughout the 
duration of pregnancy and breastfeeding, in accordance with 
DoH Guidelines,2 or even reducing the repeat testing interval 
to 1- or 2–monthly, will be crucial to ensure that maternal 
seroconversion is detected as soon as possible.
Not documenting infant NVP prophylaxis when it is 
known to be indicated occurred in 6 (42.9%) cases in our 
study. However, this is probably higher than the true value 
as, from clinical experience, we note that infant NVP is 
often administered but poorly documented. Late booking 
after 20 weeks’ gestation (also leading to late initiation of 
maternal ART) occurred in 9 (47%) of cases, although 75% 
of cases had booked before 24 weeks which should allow 
time for viral suppression by the time of delivery, assuming 
ART is initiated promptly.10,12 Omitting maternal ART 
when it is known to be indicated occurred in 3 (15.8%) cases 
(we were unable to ascertain why), and virological failure 
despite maternal cART occurred in 2 (10.5%) cases. Both 
these cases had repeated viral loads > 400 copies/mL more 
than 1 month apart but were not switched to second-line 
cART. The third case had no viral load sampling during 
pregnancy.
Weaknesses of our study include lack of a control group, 
small sample size and incomplete or unavailable case notes. 
Data were too incomplete for analysis of several important 
variables (e.g. duration and means of rupture of membranes, 
elective versus emergency caesarean section, instrumental 
delivery, postpartum maternal ART adherence). Only 
descriptive analysis was possible and our results must be 
interpreted with caution.
Conclusion
PMTCT remains a focus programme in the South African 
healthcare sector. Better understanding of the reasons for 
MTCT can assist further reduction of MTCT rates to the 
target of less than 2%. Several causes for the failure of PMTCT 
in our sub-district have been identified. These correspond 
with reasons for MTCT from previous studies and available 
literature. Late first ANC, delayed or omission of maternal 
cART initiation, and poor management of women on cART 
contributed, amongst other factors, to our MTCT cases. 
Maternal seroconversion or an initial false-negative HIV 
test occurs frequently in PMTCT failures in our clinics, with 
subsequent late maternal ART initiation. This fact highlights 
the importance of preventing and promptly detecting 
maternal HIV infection in pregnancy and breastfeeding if 
MTCT is to be further reduced. Further research is needed 
to characterise the frequency of false-negative HIV testing 
in operational PMTCT programmes, and to identify cost-
effective testing strategies to ensure early detection of acute 
maternal HIV infection in pregnancy and breastfeeding.
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